ANNOUNCEMENT

These 11 companies will be featured in the MedCity ENGAGE Innovation Showcase June 5-6 in Washington, D.C.

New (and better) buyout offer for Cold-EEZE maker ProPhase Labs

October 9, 2012 7:11 am by | 0 Comments

Matrixx Initiatives announced today that it has increased its offer to acquire all of the outstanding shares of ProPhase Labs, Inc. (NASDAQ: PRPH) by 14.3% to $1.60 per share. 

The revised offer represents a premium of 51.7% over the 30-day average closing price of ProPhase's stock and a 53.7% premium to ProPhase's average closing price over the 12 months preceding September 6, 2012 (the day ProPhase's founder and former Chairman, Guy J. Quigley, filed a Schedule 13D announcing Matrixx's purchase of a three-year option to acquire 1.45 million shares of ProPhase common stock).  Matrixx had initially proposed an all-cash acquisition of ProPhase for $1.40 per share on May 29, 2012.

"We believe our revised all-cash offer is highly attractive to ProPhase shareholders and we hope to commence discussions with ProPhase at the earliest opportunity," said Marylou W. Arnett, Chief Executive Officer of Matrixx.  "Our offer is especially attractive when considering that we believe ProPhase faces significant challenges by remaining as a standalone entity, including lack of scale,

See full press release

Advertisement
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Copyright 2013 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

By Gross, Charles

Visit website | More posts by Author

0 comments

Stay Up To Date

Recent Comments

Research Center

Jobs Board

Next Story
Sanofi Allstar insulin pen going from India to rest of South Asia
Close